Photobiomodulation Research Update - June 2026

A Busy Month for Photobiomodulation

June 2026 was a busy month for research on photobiomodulation (PBM).

After reviewing the weekly monitoring reports we track on PubMed, we identified 58 distinct publications after removing duplicates.

Some confirm already well-established uses, such as the prevention of oral mucositis in patients undergoing cancer treatment. Others are breaking new ground in areas such as cognition, sleep, multiple sclerosis, and eye strain.

Here is our breakdown by category, with links to the original articles.

A common thread emerges from month to month: the level of evidence is advancing most notably where protocols are standardized (wavelength, dose, duration). Elsewhere, the results remain promising but inconsistent, and several authors themselves point to this lack of harmonization as the main obstacle to clinical translation.

Pain and Trauma

The strongest evidence comes from a meta-analysis published in the *Annals of Medicine*: across 9 randomized trials, PBM reduced pain one week after a fracture and improved grip strength at four weeks, with no reported adverse effects. The long-term benefits and effects on bone healing remain to be demonstrated, but the evidence for pain relief in the early phase is clear (DOI).

Two randomized trials expand the scope of application to obstetrics and the postoperative period. In 104 women who had undergone cesarean sections, low-intensity infrared laser therapy reduced pain as early as the second treatment and improved scar quality, without reducing the use of pain relievers (DOI).

In 60 breastfeeding women with cracked nipples, red and infrared LLLT provided pain relief as early as 30 minutes and up to Day 7 (DOI).

A placebo-controlled trial also suggests that combining laser therapy with mechanical devices may be beneficial for low back pain (DOI).

Oncology and supportive care

This is the most significant clinical publication of the month. A randomized, sham-controlled trial involving 85 patients across 12 U.S. centers shows that an intraoral LED PBM device, applied 10 minutes before each radiation therapy session, reduces the incidence of severe mucositis (37% vs. 57%) and better preserves taste, with no adverse effects related to the device. These findings are consistent with the MASCC guidelines (DOI).

An umbrella review of 131 systematic reviews confirms the association between PBM and reduced mucositis in patients with head and neck cancer, while highlighting the heterogeneity of the evidence (DOI).

A British qualitative study provides useful insights from the field: in pediatric oncology, the adoption of PBM depends less on evidence than on local implementation conditions, and LED systems face fewer barriers than laser systems (DOI).

In terms of emerging indications, a clinical study reports a marked improvement in vaginal pain and sexual function among women being treated for breast cancer with hormone therapy (DOI).

From a mechanistic perspective, two preclinical studies qualify the long-standing concern about a pro-tumor effect: pulsed 980-nm PBM reactivates local CD8+ T-cell immunity without direct cytotoxicity (DOI), and blue light reduces the aggressiveness of oral squamous cell carcinoma cells in vitro (DOI).

Neurology and Cognition

Transcranial PBM accounts for a significant portion of this month’s activities. A randomized pilot trial in mild cognitive decline combined cognitive, mitochondrial, and imaging measures, directly linking near-infrared stimulation to brain mitochondrial function (DOI).

Another pilot study—this time an open-label trial—reports a 41% response rate in patients with treatment-resistant depression treated with an 810-nm LED headset, with good tolerability but no sham group: controlled trials are still needed (DOI).

A meta-analysis of 5 controlled trials found a modest improvement in sleep quality (PSQI score), which should be interpreted with caution given the wide confidence intervals (DOI).

In preclinical studies, research using a mouse model of Alzheimer's disease has identified two distinct mechanisms of action depending on the light regimen: continuous light strengthens astrocyte-vessel coupling, while 40-Hz stimulation promotes amyloid clearance via microglia (DOI).

Two in-depth reviews round out the picture: one on the mechanisms of PBM in multiple sclerosis (DOI), and the other on its potential in the aging brain (DOI).

Oral Health

Two findings stand out. A network meta-analysis of 41 trials involving more than 2,000 participants ranks PBM as the top non-pharmacological treatment for pain associated with myogenic temporomandibular disorders, ahead of cognitive-behavioral therapy, electrotherapy, and occlusal splints (DOI).

At the same time, a randomized, double-blind trial shows that applying an infrared LED one hour before wisdom tooth extraction reduces pain at 48 hours and accelerates the resolution of edema (DOI).

Regarding mucosal lesions, a systematic review concludes that diode laser photobiomodulation is more effective than topical treatments for aphthous stomatitis and oral lichen planus (DOI), a finding supported by an umbrella review of 41 reviews on recurrent aphthous stomatitis (DOI).

In periodontology, the addition of LLLT during gingival papilla regeneration has reduced postoperative edema and pain (DOI).

Dermatology and Aesthetics

Please note: Some of the articles identified by the “dermatology” search term pertain to ablative or vascular lasers, not photobiomodulation in the strict sense. Among the relevant studies, a randomized trial on rosacea highlights that pulse duration affects both tolerability and efficacy (DOI), and a split-face trial demonstrates the benefits of combining laser therapy with topical treatment for erythema (DOI).

A study on melasma suggests that the vascular component is more resistant to treatment, which opens the door to complementary anti-inflammatory approaches in which red light could play a role (DOI).

Finally, a review on hair restoration re-establishes LLLT as one of the treatment options for androgenetic alopecia, as part of a combination therapy approach (DOI).

Wound Healing and Chronic Wounds

Diabetic wounds remain an active area of research. A mechanistic review details how PBM restores cytochrome c oxidase and ATP production, shifts macrophages toward an M2 phenotype, and activates the VEGF and AMPK pathways, while identifying the lack of standardized parameters as the main obstacle to clinical application (DOI).

Another review explores the synergy between PBM and the secretome or exosomes of stem cells (DOI).

In terms of parameters, an in vitro study reports a synergistic effect of simultaneous stimulation at two wavelengths—655 and 808 nm—on fibroblast-mediated wound healing (DOI).

In patients with venous ulcers, a cohort study without a control group found a 92% favorable outcome rate; this result needs to be confirmed by a controlled trial (DOI).

Ophthalmology

A randomized, double-blind trial in presbyopic subjects shows that repeated low-intensity red light reduces eye strain and improves the range of accommodation at one month, with no adverse effects (DOI). A narrative review explains why the eye—which requires a great deal of mitochondrial energy—is a logical target for light therapies (DOI).

Sports, Recovery, and Cellular Mechanisms

In diabetic rats, combining respiratory muscle training with PBM reduced oxidative damage and strengthened antioxidant defenses, illustrating the synergy between light and exercise (DOI).

The most useful mechanistic finding for guiding treatment protocols comes from a study on macrophage polarization: wavelength is a game-changer, with 850 nm promoting an anti-inflammatory M2 state and 625 nm promoting a pro-inflammatory M1 state, via mitochondrial dynamics (DOI).

A recent study on stem cells highlights the existence of a narrow dose-response window, with the beneficial effect disappearing once an energy threshold is exceeded (DOI).

Key Takeaways

Three publications are raising the standard of evidence this month: the multicenter trial on radiation-induced mucositis, the network meta-analysis on temporomandibular disorders, and the meta-analysis on pain from fractures.

The rest paints a coherent picture of emerging findings—ranging from cognition to wound healing—where the real challenge lies in standardizing the parameters. It is precisely on this point—the informed choice of wavelength and dose—that the clinical credibility of PBM will hinge in the coming years.

To learn more about our devices and our approach to photobiomodulation, visit bioledtherapy.com.

Sources: PubMed / NCBI. The DOI links lead to the original publications. The abstracts are indicative summaries; please refer to the full text before any clinical application or dissemination.